Precigen (PGEN) – Research Analysts’ Recent Ratings Changes

A number of research firms have changed their ratings and price targets for Precigen (NASDAQ: PGEN):

• 5/28/2026 – Precigen had its price target raised by HC Wainwright from $11.00 to $14.00. They now have a “buy” rating on the stock.
• 5/23/2026 – Precigen was upgraded by Wall Street Zen from “hold” to “buy”.
• 5/14/2026 – Precigen had its price target raised by HC Wainwright from $10.00 to $11.00. They now have a “buy” rating on the stock.
• 5/14/2026 – Precigen had its “outperform” rating reaffirmed by Citigroup Inc..
• 5/14/2026 – Precigen had its price target raised by Citizens Jmp from $9.00 to $11.00. They now have a “market outperform” rating on the stock.
• 4/21/2026 – Precigen had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Insider Activity at Precigen

In related news, Director Randal J. Kirk sold 4,772,781 shares of the firm’s stock in a transaction on Monday, March 30th. The stock was sold at an average price of $3.30, for a total value of $15,750,177.30. Following the transaction, the director owned 302,213 shares in the company, valued at approximately $997,302.90. This trade represents a 94.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 47.10% of the company’s stock.

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.